



IN THE UNITED STATES DESIGNATED/ELECTED OFFICE

TECH CENTER 1600/2900

DEC 06 2002

RECEIVED

In re Application of:

Klaus STÖCKEMANN et al.

Art Unit: 1654

Serial No.: 09/117,357 ✓

Examiner: C. Delacroix-Muirheid

Filed: September 22, 1998

Title: PHARMACEUTICAL COMBINED PREPARATION AND ITS USE IN THE TREATMENT OF GYNAECOLOGICAL DISORDERS

REPLY

Sir:

In response to the Office Action of October 22, 2002, please amend the above identified application as follows:

IN THE SPECIFICATION

At page 6, lines 11-15, delete the paragraph and replace it with the following new paragraph.

--The anti-oestrogens mentioned are known. For example, Raloxifen is 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(2-piperidinyloethoxy)benzoyl]benzo[b]thiophene. In combination with parathyroid hormone, Raloxifen and its derivatives are used to increase bone mass. EP 0635 270 discloses that raloxifene is described in US patent No. 4,418,068 and that EP-A-584952 discloses that raloxifene is useful in the inhibition or prevention of bone loss.--

IN THE CLAIMS:

Please amend the following claims as follows:

--46. A method according to claim 45, wherein Raloxifen is administered orally.--